Presentations :: Syros Pharmaceuticals, Inc. (SYRS)

SELECT-AML-1: Initial Randomized Data Evaluating Tamibarotene in Newly Diagnosed AML Patients Ineligible for Standard Induction Therapy Data Presentation

SELECT-AML-1: Initial Randomized Data Evaluating Tamibarotene in Newly Diagnosed AML Patients Ineligible for Standard Induction Therapy Data Presentation